bioAffinity Q2 2025 net loss $4.1M; CyPath Lung revenue up 62% H1

bioAffinity Technologies, Inc.

2025-Q2 EPS reported -$0.20 revenue$3,123,080

Total revenue $1.3M in Q2 2025 vs $2.4M in Q2 2024, reflecting discontinuation of unprofitable pathology services.
CyPath Lung testing revenue grew 62% YTD to $323K; monthly tests set records in June and July.
Net loss $4.1M ($0.17/share) vs $2.1M ($0.19/share) in Q2 2024, increase driven by non-cash warrant remeasurement and offering costs.
Cash $0.8M at June 30, 2025; completed $3.25M public offering in May 2025 to bolster working capital.
Appointed Dr. Gordon Downie as CMO; expanded IP portfolio with patents in US, China, Canada, Australia.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.